A biopharmaceutical company developing and commercializing novel oral therapeutics for rare hematology diseases, primarily focusing on mavorixafor, a small-molecule CXCR4 antagonist. The company's sole FDA-approved product, XOLREMDI (mavorixafor), treats WHIM syndrome, an ultra-rare inherited combined immunodeficiency disorder, with the company also advancing mavorixafor in clinical trials for chronic neutropenia where it demonstrates potential as an oral monotherapy or combination option for patients who are naive to, intolerant of, or unresponsive to current injectable treatments. The company generates revenue through product sales and licensing agreements with global commercialization partners, including milestone payments and tiered royalties, while manufacturing is outsourced to third-party contractors.